LifeStance Q2 revenue up 20% to $312M; raises FY2024 guidance on strong margins

LifeStance Health Group, Inc.

Revenue $312.3M (+20% YoY); net loss narrowed to $23.3M from $45.5M; Adjusted EBITDA $28.6M (+103%).
Center Margin improved to 31.3% of revenue (28.1% prior year); clinician base up 14% to 6,984.
FY2024 guidance raised: revenue $1.2B-$1.242B, Adjusted EBITDA $90M-$100M; expects positive free cash flow.
Q3 2024 guidance: revenue $290M-$310M, Adjusted EBITDA $15M-$21M.
Cash $87M, net debt $279.5M; operating cash flow $44.1M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.